Fondaparinux Sodium (Org 31540)

Catalog No.S3736 Synonyms: Natural heparin pentasaccharide Sodium, Fondaparin sodium, SR-90107A

For research use only.

Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.

Fondaparinux Sodium (Org 31540) Chemical Structure

CAS No. 114870-03-0

Purity & Quality Control

Choose Selective Factor Xa Inhibitors

Other Factor Xa Products

Biological Activity

Description Fondaparinux Sodium (Org 31540, Natural heparin pentasaccharide, Fondaparin, SR-90107A) is a synthetic glucopyranoside with antithrombotic activity. It selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin; a synthetic inhibitor of Factor Xa.
Targets
Factor Xa [1]
()
In vitro

Fondaparinux is a synthetic pentasaccharide that selectively inhibits factor Xa (FXa) in the coagulation cascade. Fondaparinux has been shown to inhibit the TF-FVIIa complex and FIXa in vitro[1].

In vivo Fondaparinux reduces kidney I/R injury primarily by inhibiting the recruitment of neutrophil. It dramatically reduced fibrin deposition in the kidney[1]. Fondaparinux can promote the stability of atherosclerotic lesions in apolipoprotein E-deficient mice, possibly through inhibiting expression of the inflammatory mediators in plaque and reduced synthesis of MMP-9 and MMP-13[2].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: U937 cells
  • Concentrations: 0-100 μg/ml
  • Incubation Time: 30 min
  • Method:

    Fondaparinux was diluted in PBS to a total volume of 50 μL and added to the wells. Labeled U937 cells (50 μL) were then added and incubated at room temperature for 30 min. Finally, the wells were washed three times with PBS and cells were lyzed using 2% Triton X-100 in 0.1 mol/L Tris-HCl pH 9.5.

Animal Research:

[1]

  • Animal Models: Murine model of kidney I/R (background: C57BL/6)
  • Dosages: 5-10 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Water 100 mg/mL
(57.86 mM)
DMSO 1 mg/mL
(0.57 mM)
Ethanol Insoluble

Chemical Information

Molecular Weight 1728.08
Formula

C31H43N3O49S8.10Na

CAS No. 114870-03-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1C(C(C(C(O1)COS(=O)(=O)[O-])OC2C(C(C(C(O2)C(=O)[O-])OC3C(C(C(C(O3)COS(=O)(=O)[O-])OC4C(C(C(C(O4)C(=O)[O-])OC5C(C(C(C(O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00436787 Completed Drug: Fondaparinux Sodium Venous Thrombosis|Pulmonary Embolism University of Pittsburgh|GlaxoSmithKline February 2007 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fondaparinux Sodium (Org 31540) | Fondaparinux Sodium (Org 31540) supplier | purchase Fondaparinux Sodium (Org 31540) | Fondaparinux Sodium (Org 31540) cost | Fondaparinux Sodium (Org 31540) manufacturer | order Fondaparinux Sodium (Org 31540) | Fondaparinux Sodium (Org 31540) distributor